SCHEMBL1483284

SCHEMBL1483284

CC(=O)c1nn(C)c(-c2cccc(C(F)(F)F)c2)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
MEN1 O00255 1/20 0.46
FYN P06241 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
PLK1 P53350 1/20 0.43
CCNA1 P78396 1/20 0.43
NPC1 O15118 1/20 0.43
ATM Q13315 1/20 0.43
AKR1C3 P42330 1/20 0.43
TSHR P16473 1/20 0.43
PIN1 Q13526 1/20 0.43
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
TOP2A P11388 1/20 0.42
KMO O15229 1/20 0.41
TGFBR1 P36897 1/20 0.41
POLB P06746 2/20 0.41
GRM5 P41594 1/20 0.41
DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL277330 0.84 GRM5 (0.49) CCNA2CDK2PLK1CCNA1NPC1
SCHEMBL12755603 0.80 KMT2A (0.47) KMT2AMEN1NPC1ATMMAPT
SCHEMBL2200888 0.80 PIN1 (0.54) KMT2AMEN1NPC1ATMPIN1
SCHEMBL280162 0.79 CSF1R (0.46) KMT2AMEN1CCNA2CDK2PLK1
SCHEMBL1483431 0.78 MEN1 (0.43) KMT2AMEN1NPC1ATMMAPT
SCHEMBL12829633 0.78 MEN1 (0.43) KMT2AMEN1NPC1ATMMAPT
SCHEMBL1483429 0.78 MEN1 (0.43) KMT2AMEN1NPC1ATMMAPT
SCHEMBL1483463 0.77 MAPT (0.42) KMT2AMEN1NPC1ATMMAPT
SCHEMBL1483461 0.77 MAPT (0.42) KMT2AMEN1NPC1ATMMAPT
SCHEMBL21326167 0.77 PIN1 (0.48) KMT2AMEN1NPC1ATMPIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636192-B9 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2015-07-01 EP disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
EP-1636192-B1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2014-01-15 EP disclosed
US-20130012708-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2013-01-10 US disclosed
US-8318796-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-11-27 US disclosed
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2011-03-31 US disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3762/4885MEN1 2583/4885FYN 202/4885
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 KMT2A 3696/4885MEN1 2504/4885FYN 185/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3797/4885MEN1 2551/4885FYN 213/4885
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3762/4885MEN1 2583/4885FYN 202/4885
US-20130012708-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3762/4885MEN1 2583/4885FYN 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.